Bionano Genomics, Inc. Proceeds from Common Stock Issued
Bionano Genomics, Inc. (BNGO) reported Proceeds from Common Stock Issued of $1.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-10
- Bionano Genomics, Inc. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $620.00K, a 79.94% decline year-over-year.
- Bionano Genomics, Inc. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $705.00K, a 94.71% decline year-over-year.
- Bionano Genomics, Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $1.75M, a 73.95% decline year-over-year.
- Bionano Genomics, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $12.94M, a 27.98% increase year-over-year.
- Bionano Genomics, Inc. proceeds from issuance of common stock for fiscal 2025 was $31.10M, a 30.01% decline from fiscal 2024.
- Bionano Genomics, Inc. proceeds from issuance of common stock for fiscal 2024 was $44.43M, a 22.99% decline from fiscal 2023.
- Bionano Genomics, Inc. proceeds from issuance of common stock for fiscal 2023 was $57.70M, a 149.47% increase from fiscal 2022.
- Bionano Genomics, Inc. proceeds from issuance of common stock for fiscal 2022 was $23.13M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $620.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.32M 10-Q · filed 2026-08-10 | $3.08M derived: sum of 3 quarters · filed 2026-08-10 | $16.02M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $705.00K 10-Q · filed 2026-05-13 | $2.46M derived: sum of 2 quarters · filed 2026-05-13 | $15.39M derived: sum of 3 quarters · filed 2026-05-13 | $18.49M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $14.69M derived: sum of 2 quarters · filed 2026-03-23 | $17.78M derived: sum of 3 quarters · filed 2026-08-10 | $31.10M 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $12.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $16.03M derived: sum of 2 quarters · filed 2026-08-10 | $29.35M 10-Q · filed 2025-11-13 | $36.07M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $16.41M 10-Q · filed 2026-08-10 | $23.13M derived: sum of 3 quarters · filed 2026-08-10 | $33.24M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $13.32M 10-Q · filed 2026-05-13 | $20.04M derived: sum of 2 quarters · filed 2026-05-13 | $30.15M derived: sum of 3 quarters · filed 2026-05-13 | $42.30M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $16.83M derived: sum of 2 quarters · filed 2026-03-23 | $28.99M derived: sum of 3 quarters · filed 2026-03-23 | $44.43M 10-K · filed 2026-03-23 | ||
| 2024-09-30 | $10.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $22.27M derived: sum of 2 quarters · filed 2025-11-13 | $37.71M 10-Q · filed 2025-11-13 | $49.00M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $12.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $27.60M 10-Q · filed 2025-08-14 | $38.89M derived: sum of 3 quarters · filed 2025-08-14 | $51.81M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $15.45M 10-Q · filed 2025-05-14 | $26.73M derived: sum of 2 quarters · filed 2025-05-14 | $39.66M derived: sum of 3 quarters · filed 2025-05-14 | $57.91M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $11.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $24.21M derived: sum of 2 quarters · filed 2025-03-31 | $42.47M derived: sum of 3 quarters · filed 2025-03-31 | $57.70M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $12.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $31.18M derived: sum of 2 quarters · filed 2024-11-14 | $46.41M 10-Q · filed 2024-11-14 | $46.41M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $18.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $33.49M 10-Q · filed 2024-08-07 | $33.49M derived: sum of 3 quarters · filed 2024-08-07 | $56.62M derived: sum of 4 quarters · filed 2024-08-07 | ||
| 2023-03-31 | $15.23M 10-Q · filed 2024-05-08 | $15.23M derived: sum of 2 quarters · filed 2024-05-08 | $38.36M derived: sum of 3 quarters · filed 2024-05-08 | $38.36M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $23.13M derived: sum of 2 quarters · filed 2024-03-05 | $23.13M derived: sum of 3 quarters · filed 2024-03-05 | $23.13M 10-K · filed 2024-03-05 | ||
| 2022-09-30 | $23.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $23.13M derived: sum of 2 quarters · filed 2023-11-08 | $23.13M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||||
| 2021-09-30 | $14.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $14.08M derived: sum of 2 quarters · filed 2022-11-03 | $342.71M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $328.63M 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $328.63M 10-Q · filed 2022-05-05 | |||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $17.96M derived: sum of 2 quarters · filed 2021-11-04 | $17.96M 10-Q · filed 2021-11-04 | $16.37M 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | $17.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $17.96M 10-Q · filed 2021-08-04 | $16.37M 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | |||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $0.00 derived: sum of 2 quarters · filed 2020-11-13 | $2.41M 10-Q · filed 2020-11-13 | $2.41M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $2.41M 10-Q · filed 2020-08-13 | $2.41M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $2.41M 10-Q · filed 2020-06-18 | |||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |